FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 711 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... July 22, 2025 38% of Recurrent Breast Cancers Have a Different HER2 Status than... May 25, 2021 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early... January 18, 2022 Load more HOT NEWS Cancer in My Community: Expanding Genetic Testing in Thailand News digest – skin cancer deaths, Public Health England plans and... EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced...
